Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
1. Alnylam's vutrisiran receives positive opinion from EMA CHMP for ATTR-CM treatment.
FAQ
Why Very Bullish?
A positive EMA opinion may lead to market approval, potentially increasing revenue, as seen with past drug approvals by Alnylam, significantly boosting stock value.
How important is it?
The approval of vutrisiran can enhance Alnylam's growth and stability, positively impacting its stock.
Why Short Term?
If approval follows soon, immediate market reaction and increased sales could occur.